Pharma News

Boehringer Ingelheim licenses a preclinical antibody program from Immunitas Therapeutics to treat chronic inflammatory diseases in a deal worth up to €407.5M.

ModeX Therapeutics will present preclinical data on MDX3001 at ASGCT 2026, showcasing in vivo CAR-T cell generation using an antibody-conjugated LNP platform.

Inhibrx Biosciences reveals positive interim Phase II data for INBRX-106 and pembrolizumab combination in treating advanced head and neck squamous cell cancer.

Bristol Myers Squibb and Hengrui Pharma announce a $15.2B licensing deal for early-stage oncology, immunology, and haematology assets to combat patent cliffs.

Revolution Medicines’ daraxonrasib shows promising clinical results for metastatic pancreatic cancer, targeting previously undruggable KRAS mutations.

British paratroopers and medics conducted a historic airdrop over Tristan da Cunha to deliver vital oxygen and care for a suspected hantavirus patient.

The FDA has approved Partner Therapeutics' Bizengri for adults with a rare form of advanced bile duct cancer under a new Fast-Track review program.

Viridian Therapeutics reports positive Phase 3 REVEAL-2 data for elegrobart, a subcutaneous IGF-1R antibody for chronic thyroid eye disease (TED).

Tvardi Therapeutics faces a critical juncture with its STAT3 inhibitors, TTI-101 and TTI-109, as clinical readouts align with a narrowing cash runway.

Ernexa Therapeutics announced preclinical data showing ERNA-101 combined with PD-1 blockade achieved complete tumor clearance in ovarian cancer models.

Italy's Angelini Pharma has agreed to acquire Catalyst Pharma for up to $4.1 billion, gaining FDA-approved neurological drugs and entering the U.S. market.

Daiichi Sankyo partnered with Waiv to leverage its AI computational pathology platform for ADC biomarker discovery, aiming to enhance clinical trial success.